CLINICAL TRIAL SUMMARY

MDACC Study No:2005-0054 (clinicaltrials.gov NCT No: NCT00290498)
Title:A Phase II Randomized Study of Rituximab-HCVAD alternating with Rituximab-Methotrexate-Cytarabine versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger
Principal Investigator:Luis E. Fayad
Treatment Agent:Cyclophosphamide; Cytarabine; Doxorubicin; Hyper-CVAD; Methotrexate; Prednisone; Rituximab; Vincristine
Study Status:Closed
Study Description:The overall goal of this clinical research study was to find out which of two
different chemotherapy drug combinations, R-CHOP and R-HCVAD, is more effective
in treating B-cell lymphoma.

At this point, all participants will now be assigned to the R-HCVAD arm of the
study. Researchers will study the safety and effectiveness of this drug
combination.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Cyclophosphamide
Cytarabine
Doxorubicin
Hyper-CVAD
Methotrexate
Prednisone
Rituximab
Vincristine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:not applicable
Supported By:N/A
Return Visit:Every 3 weeks during treatment (21 day cycles). After treatment: every 6
months for years 1,2, 3 and 4 for restaging; yearly afterwards if clinically
indicated
Home Care:not applicable


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Luis E. Fayad
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults